Literature DB >> 14076169

A CONTROLLED TRIAL OF DIGOXIN IN THE PREVENTION OF THE RESPIRATORY DISTRESS SYNDROME.

J K MARTIN.   

Abstract

The possibility that cardiac failure may be an important contributory or additive factor has led to the sporadic use of digitalis in the treatment of the respiratory distress syndrome in newborn infants. To assess the value of such medication a double-blind controlled study was conducted on 196 newborn infants, using digoxin and a placebo. As a result of the findings in this study the routine use of digoxin for the prevention of the respiratory distress syndrome is not recommended. The toxic effects of digitalis are outlined.

Entities:  

Keywords:  ASPHYXIA NEONATORUM; DIGOXIN; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; PLACEBOS; TOXICOLOGIC REPORT

Mesh:

Substances:

Year:  1963        PMID: 14076169      PMCID: PMC1921909     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  5 in total

1.  Neonatal pulmonary disorders.

Authors:  S G DRISCOLL; C A SMITH
Journal:  Pediatr Clin North Am       Date:  1962-05       Impact factor: 3.278

2.  The pulmonary hyaline membrane as a manifestation of heart failure in the newborn infant.

Authors:  F C LENDRUM
Journal:  J Pediatr       Date:  1955-08       Impact factor: 4.406

3.  Digoxin dosage in premature infants.

Authors:  O R LEVINE; S BLUMENTHAL
Journal:  Pediatrics       Date:  1962-01       Impact factor: 7.124

4.  Digitalis intoxication in premature infants.

Authors:  O R LEVINE; A P SOMLYO
Journal:  J Pediatr       Date:  1962-07       Impact factor: 4.406

5.  A caution about digoxin dosage in infants and young children.

Authors:  S KAPLAN
Journal:  Pediatr Clin North Am       Date:  1962-11       Impact factor: 3.278

  5 in total
  1 in total

Review 1.  Digoxin for preventing or treating neonatal respiratory distress syndrome.

Authors:  Roger Soll; Eren Ozek
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.